Physician profile
Laura Beals
NPI 1477158699
$2,593.66
in general payments reported to CMS, 2019-2025
28 companies · $82.13 in 2025
The $82.13 reported for 2025 was less than what a typical Oncology (Registered Nurse) provider received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $425 · 2023: $885 · 2024: $926 · 2025: $82.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $247.00 | 2021-2024 | Enhertu, Lynparza |
| Gilead Sciences, INC. | $209.27 | 2022-2024 | Trodelvy |
| Pfizer INC. | $200.08 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.58 | 2022-2024 | Ninlaro, Iclusig |
| Seagen INC. | $171.19 | 2021 | |
| Merck Sharp & Dohme LLC | $168.38 | 2022-2024 | Keytruda, Lynparza |
| Abbvie INC. | $143.24 | 2023-2025 | |
| Daiichi Sankyo INC. | $142.01 | 2022-2025 | Enhertu |
| Glaxosmithkline, LLC. | $132.67 | 2023-2024 | Ojjaara, Jemperli, Zejula |
| Beigene USA, INC. | $107.58 | 2023-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $103.93 | 2022-2023 | Imbruvica |
| Amgen INC. | $102.57 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Celgene Corporation | $93.74 | 2021-2023 | Opdualag, Pomalyst |
| Karyopharm Therapeutics INC. | $85.46 | 2021-2023 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $79.23 | 2022-2024 | Libtayo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $58.04 | 2022-2024 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $55.35 | 2022-2023 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $42.04 | 2023 | |
| Genentech USA, INC. | $38.38 | 2022 | |
| Sobi, INC | $36.77 | 2023-2024 | |
| Eisai INC. | $36.04 | 2022-2023 | |
| Epizyme, INC. | $32.47 | 2021-2023 | Tazverik |
| Astellas Pharma US INC | $27.93 | 2024 | Padcev |
| Tersera Therapeutics LLC | $27.48 | 2024 | Zoladex |
| Incyte Corporation | $20.59 | 2023 | Jakafi |
| Acrotech Biopharma INC. | $17.37 | 2024 | Beleodaq |
| Servier Pharmaceuticals LLC | $15.41 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.86 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Beals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.